MedTrace Logo

Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer

NCT05302778 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-05-25

No results posted yet for this study

Summary

Multicenter, retrospective and prospective, cohort, observational study evaluating the clinical efficacy and tolerability of Eribulin as second-line treatment in accordance with the indications authorized by AIFA in patients with triple negative advanced breast cancer in a real world setting.

Conditions

Sponsors & Collaborators

  • EISAI s.r.l.

    collaborator UNKNOWN

  • University of Milano Bicocca

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05302778 on ClinicalTrials.gov